norstella-logo-white

Resources

Toggle Filters
Article icon
Article

Biopharma’s R&D engine and the...

One of the main topics of conversation at the beginning of 2025 is how pharma companies should build their pipelines and the rising role that China is playing. A widely-cited report from Stifel showed that 30%...
Read the article
Article icon
Article

Spotlight on India: A booming...

In a series exploring trends across the APAC region, Norstella’s subject matter experts from key biopharma hubs delve into last year’s standout developments and share their outlook for 2025. Andrew Warmington, Manufacturing Editor at Citeline, spoke...
Read the article
Ebook icon
Ebook

The greatest opportunities to enhance...

The pharma industry continues to persevere through talent shortages, supply chain disruptions, data challenges, and many more obstacles that are making it increasingly difficult to get life-saving treatments to patients. However, the thirst for innovation and...
Download the ebook
Article icon
Article

Spotlight on Japan: A supportive...

In a series exploring trends across the APAC region, Norstella’s subject matter experts from key biopharma hubs delve into this year’s standout developments and share their outlook for 2025. Andrew Warmington, Manufacturing Editor at Citeline, spoke...
Read the article
Article icon
Article

Harnessing the power of RWE...

Real-world evidence (RWE) is becoming increasingly important in driving pharmaceutical innovations, as it helps researchers to understand the settings in which a drug, medical device, or other treatment is applied, such as innovation, care patterns, and...
Read the article
White paper icon
White paper

Innovation trends from R&D to...

2024 has been an incredibly busy year for Norstella as its constituent organizations – Citeline, Evaluate, MMIT, Panalgo, and the Dedham Group – have continued to support the biopharma ecosystem in bringing new therapies to patients....
Download the white paper
Report icon
Report

Assessing AI transformation in pharma...

Artificial intelligence (AI) has been one of the largest disruptors in drug development over the past few years, with the promise of innovation and greater efficiencies keeping the pharma industry heavily invested. There have been major...
Download the report
category
Article

Harnessing lab data to speed... Harnessing lab data to speed time to treatment

In recent years, pharma companies have begun to embrace lab data as a richly rewarding...
View resource
category
Podcast

Conference catch-up: Collaboration and innovation... Conference catch-up: Collaboration and innovation in biopharma

The biopharma industry is evolving, with increased focus on partnerships, early-phase deal-making and technologies like...
View resource
category
Article

Spotlight on China: A dominant... Spotlight on China: A dominant player in the clinical trial landscape

In a series exploring trends across the APAC region, Norstella’s subject matter experts from key...
View resource
category
Video

Level up your lab data:... Level up your lab data: New use cases for improving time to treatment

Real-world data is essential to gaining insights into a patient’s diagnostic journey, but many pharma...
Watch the video
category
Podcast

Conference catch-up: Navigating the evolving... Conference catch-up: Navigating the evolving CDMO landscape

Contract development and manufacturing organizations (CDMOs) are reshaping pharmaceutical production, playing a pivotal role in...
View resource
category
Article

Assessing current AI trends in... Assessing current AI trends in drug development: Adoption and transformation (part 1)

Pharmaceutical R&D is undergoing significant changes. The need to accelerate drug development and enhance decision-making...
View resource
category
Podcast

Conference catch-up: The rise of... Conference catch-up: The rise of digital therapeutics (part 2)

Health technologies are revolutionizing the ways in which life sciences organizations develop and deliver life-saving...
View resource
category
Infographic

The current & future impact... The current & future impact of AI on pharmaceutical R&D

Artificial intelligence (AI) continues to disrupt existing paradigms in drug development, with early adopters experiencing...
View resource
category
In the news

Norstella rolls out NorstellaLinQ data... Norstella rolls out NorstellaLinQ data platform

Norstella LinQ establishes a throughline between the company’s various subsidiaries, utilizing capabilities from Citeline, Evaluate,...
View resource
category
Article

The practice-changing drugs that will... The practice-changing drugs that will land in 2025

2025 promises to represent another rich year of progress. A wealth of new therapies are...
View resource
category
Podcast

Conference catch-up: The rise of... Conference catch-up: The rise of digital therapeutics (part 1)

Healthcare technologies are revolutionizing the ways in which life sciences organizations develop and deliver life-saving...
View resource
category
Article

Pharma’s future: More with less Pharma’s future: More with less

2023 saw the biopharmaceutical industry spend a record $300bn on R&D activities, reinvesting approximately 30%...
View resource